Outcomes 2019 - Baylor Scott & White Heart and Vascular Hospital BSWHHVH_646_2019 Outcomes JOOMAG MOD | Página 40

40 WISCR – Wound Imaging Study to Gather Clinical References for a Device to Assist Selecting Level-of-Amputation in PAD Patients Baylor Scott & White Heart and Vascular Hospital - Dallas was an enrolling site for this study that gathered data to train the CADe algorithm to predict ultimate healing status of tissue in the lower extremities of individuals living with PAD. The investigators focused on demonstrating the feasibility of using such an algorithm to accurately predict the location and extent of small vessel disease prior to amputation. Eventually, the investigators expect the DeepView ® imaging device developed by SpectralMD to help reduce the rate of re-amputation in patients with PAD if used for routine assessment of patients prior to amputation. Stephen Hohmann, MD, is the principal investigator. The study remains open beyond fiscal year 2019 and is currently enrolling patients. For more information, contact the study coordinator, Merielle Boatman, at 214.820.2273. Complex dialysis access Clinical studies and continued research in the area of complex dialysis access is a mainstay for the vascular surgery division. In fiscal year 2019, vascular surgeons on the hospital’s medical staff continued to see an increasing number of referrals from throughout Texas and the greater Southwest region for complex dialysis access procedures. The team continues to support the National Kidney Foundation’s “Fistula First” initiative with the goal of providing fistulas for the end-stage renal disease patient population in concert with the goals of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative (NKF NDOQI). Baylor Scott & White Heart and Vascular Hospital – Dallas was the first site in the US, and Stephen Hohmann, MD, a vascular surgeon on the hospital’s medical staff was the first surgeon to deploy the BD WavelinQ™ 4F EndoAVF System, a new and innovative treatment option for patients with End-Stage Renal Disease (ESRD). The BD WavelinQ technology enables vascular surgeons on the Baylor Scott & White Heart and Vascular Hospital – Dallas medical staff to provide ESRD patients with two additional fistula location options that are less invasive compared to a surgical fistula. Using this approach can help create and maintain AV access for patients on hemodialysis, which is an important expansion of the hospital’s complex dialysis access program. Clinical study: Humanity trial Together with Humacyte, a biotechnology and regenerative medicine company, vascular surgeons on the medical staff at Baylor Scott & White Heart and Vascular Hospital – Dallas have continued investigational work with human acellular vessel (HAV) Phase III clinical study as a conduit for hemodialysis in patients with end-stage renal disease and who are not candidates for a fistula. As one of the national and international trial sites in fiscal year 2019, Baylor Dallas’ HUMANITY trial is one of the largest studies of any bioengineered vascular tissues to date. The Dallas site’s primary investigator is Stephen Hohmann, MD.